Lisi Paolo, Bellini Veronica, Bianchi Leonardo
Section of Clinical, Allergological and Venereological Dermatology, Department of Medicine, University of Perugia, Perugia, Italy.
Oncology. 2014;87(5):311-9. doi: 10.1159/000365994. Epub 2014 Aug 29.
Skin toxicity is frequent and debilitating in oncologic patients treated with epidermal growth factor receptor inhibitors (EGFRIs). Grading and management of skin adverse events (AEs) are poorly standardized.
We developed a new score (EGFRISTI: Epidermal Growth Factor Receptor Inhibitor-Related Skin Toxicity Index) which is able to quantify and monitor all EGFRI-related dermatologic AEs over time. The utility of this tool was validated in 130 patients treated with 5 different EGFRIs including both monoclonal antibodies and tyrosine kinase inhibitors.
The mean baseline EGFRISTI score was 26.9 (range: 6.0-64.5). Mild toxicity was found in 55 patients (42.3%), moderate toxicity in 43 (33.1%), and severe toxicity in 32 patients (24.6%). After the first-line toxicity treatment, an EGFRISTI score reduction of >75% was obtained in 31 patients (34.1%) and one of 50% in 40 patients (43.9%), while an improvement of <50% was observed in the remaining 20 subjects (22.0%).
The EGFRISTI is a simple and reliable tool to quantify and express the severity of all clinical signs and symptoms of EGFRI skin toxicity with a single numerical value, to choose the most suitable therapy, and to measure its efficacy.
在接受表皮生长因子受体抑制剂（EGFRIs）治疗的肿瘤患者中，皮肤毒性很常见且令人虚弱。皮肤不良事件（AEs）的分级和管理标准化程度很低。
我们开发了一种新的评分系统（EGFRISTI：表皮生长因子受体抑制剂相关皮肤毒性指数），它能够随时间量化和监测所有与EGFRIs相关的皮肤AEs。该工具的实用性在130例接受5种不同EGFRIs治疗的患者中得到验证，这些EGFRIs包括单克隆抗体和酪氨酸激酶抑制剂。
EGFRISTI的平均基线评分为26.9（范围：6.0 - 64.5）。55例患者（42.3%）出现轻度毒性，43例（33.1%）出现中度毒性，32例患者（24.6%）出现重度毒性。一线毒性治疗后，31例患者（34.1%）的EGFRISTI评分降低>75%，40例患者（43.9%）降低50%，其余20例患者（22.0%）的改善<50%。
EGFRISTI是一种简单可靠的工具，可通过单一数值量化并表达EGFRIs皮肤毒性所有临床体征和症状的严重程度，选择最合适的治疗方法，并衡量其疗效。
